A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF.
This application is a divisional of Ser. No. 08/894,873 filed Aug. 4, 1997 now U.S. Pat. No. 5,863,949, which is a 371 of PCT/US 96/02679 filed Mar. 7, 1996.
A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.
The present invention relates to novel bioisosteres of the antibiotic actinonin of the general formula (I). The novel compounds are of particular interest as inhibitors of metalloproteinases. ##STR00001##
Provided are compounds of formula (I) ##STR1## wherein A, Q, W, X, Y, Z, R.sub.1 to R.sub.4, m and n are as defined herein. Compounds of the invention bind to .alpha..sub.4 integrin receptors and thereby inhibit binding of ligands for .alpha..sub.4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with .alpha..sub.4 integrins or their ligands.
Provided are compounds of formula (I) ##STR00001## wherein A, Q, W, X, Y, Z, R.sub.1 to R.sub.4, m and n are as defined herein. Compounds of the invention bind to .alpha..sub.4 integrin receptors and thereby inhibit binding of ligands for .alpha..sub.4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with .alpha..sub.4 integrins or their ligands.
Provided are compounds of formula (I) ##STR1## wherein A, Q, W, X, Y, Z, R.sub.1 to R.sub.4, m and n are as defined herein. Compounds of the invention bind to .alpha..sub.4 integrin receptors and thereby inhibit binding of ligands for .alpha..sub.4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with .alpha..sub.4 integrins or their ligands.
